PhaseV vs Figma
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $50M Series A (May 2025) co-led by Accel and Insight Partners. Cuts trial costs 50%, enrollment 40%, duration 40%. 40+ pharma sponsors. 7 of world's top pharma companies as partners.
About
PhaseV is an AI clinical trial platform that uses predictive analytics to optimize trial design, site selection, patient enrollment, and protocol adherence — delivering dramatic efficiency improvements over traditional trial execution. The company raised $50 million in Series A financing in May 2025 co-led by Accel and Insight Partners, and entered 2026 with 40+ global pharmaceutical sponsors as customers including 7 of the world's top pharmaceutical companies.
Dominant browser-based collaborative UI design platform at ~$600M ARR and $12.5B valuation; Adobe's $20B acquisition blocked by regulators in 2023, Figma remains independent competing with Sketch and Adobe.
About
Figma is a San Francisco-based collaborative web-based product design platform that has become the dominant tool for UI/UX designers and product teams — enabling real-time multi-user collaboration on interface design, prototyping, and design system management directly in the browser without installing desktop software. Founded in 2012 by Dylan Field and Evan Wallace and backed by Sequoia, Greylock, and Andreessen Horowitz with over $330 million raised, Figma generated approximately $600 million in ARR in 2023, serving 4 million+ designers and product teams at companies including Microsoft, Airbnb, Twitter, and Uber. Adobe announced a $20 billion acquisition offer in 2022, which was blocked by regulators in 2023 — Figma remains independent.
AI Visibility Head-to-Head
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.